Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

bluebird bio Inc.

www.bluebirdbio.com

Latest From bluebird bio Inc.

Rare Disease Gene Therapy Guidance Gives More Flexibility On Placebo-Controlled Trials

US FDA declined stakeholder requests to remove recommendation for placebo controls from a final guidance but added qualifying language on their use ‘when feasible.’ While the agency excised language on biomarker validation from the final guidance, it reaffirmed the need for early establishment of critical quality attributes and critical process parameters.

Gene Therapy Rare Diseases

BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?

Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.

Commercial Companies

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.

Gene Therapy Launches

2020 Could Spell The End Of Mega-Mergers, For Now

Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Neurology, Nervous System
  • Alias(es)
  • bluebird bio LLC
  • bluebird bio LLC
  • Genetix Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • bluebird bio Inc.
  • Senior Management
  • Nick Leschly, Pres. & CEO
    Chip Baird, CFO
    Philip Gregory, CSO
    David Davidson, MD, CMO
    Joanne Smith-Farrell, PhD, CBO
    Alison Finger, Chief Commercial Officer
  • Contact Info
  • bluebird bio Inc.
    Phone: (339) 499-9300
    60 Binney St.
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register